Literature DB >> 2073114

Cilofungin (LY121019) shows nonlinear plasma pharmacokinetics and tissue penetration in rabbits.

J W Lee1, P Kelly, J Lecciones, D Coleman, R Gordee, P A Pizzo, T J Walsh.   

Abstract

We studied the plasma pharmacokinetics and tissue penetration of cilofungin (LY121019), a new echinocandin antifungal compound, by intermittent and continuous infusion in rabbits. Following a single intravenous dose of 50 mg/kg of body weight, the maximum concentration in plasma was 297 +/- 39 micrograms/ml, the area under the curve was 30.1 +/- 6.7 micrograms.h/ml, clearance was 30 +/- 10 ml/min/kg, volume of distribution was 0.85 +/- 0.23 liters/kg, half-life in distribution phase was 3.7 +/- 0.2 min (first 12 min postdose), and half-life in elimination phase was 12.9 +/- 0.7 min. When rabbits received cilofungin by continuous infusion (CI) at 10 mg/kg/h over 6 days, sustained concentrations in plasma of 290 +/- 56 micrograms/ml were seen, more than 50-fold higher than predicted if kinetics were linear. Similarly, at 5 mg/kg/h, high levels were also obtained. Such elevated levels in plasma would not have been predicted from the pharmacokinetic characteristics of cilofungin given as a single intravenous dose. Further pharmacokinetic study at several rates of CI suggested that cilofungin elimination follows Michaelis-Menten kinetics. Simultaneous cilofungin levels in plasma and tissue were then determined for rabbits receiving six intravenous, intermittent doses (ID) of cilofungin at 15 mg/kg every 4 min and for rabbits receiving CI as described above. After ID, the mean of the ratios of cilofungin levels in tissue to those in plasma were highest for liver and bile but very low for cerebrum and cerebellum. After CI, ratios were as much as 89 times higher than for ID and significantly greater in the brain, choroid, kidney, and bile (P less than 0.05). We conclude that following a single dose of cilofungin, the compound is rapidly cleared via first-order kinetics and does not penetrate into the central nervous system, whereas following CI, cilofungin exhibits nonlinear saturable kinetics, is slowly cleared, and significantly penetrates into central nervous system tissues.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2073114      PMCID: PMC172029          DOI: 10.1128/AAC.34.11.2240

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  Systemic fungal infections: diagnosis and treatment. I. Therapeutic agents.

Authors:  J R Graybill
Journal:  Infect Dis Clin North Am       Date:  1988-12       Impact factor: 5.982

2.  Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits.

Authors:  T J Walsh; J Bacher; P A Pizzo
Journal:  Lab Anim Sci       Date:  1988-08

3.  Treatment of experimental disseminated candidiasis with cilofungin.

Authors:  J R Perfect; M M Hobbs; K A Wright; D T Durack
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

4.  Effects of preventive, early, and late antifungal chemotherapy with fluconazole in different granulocytopenic models of experimental disseminated candidiasis.

Authors:  T J Walsh; S Aoki; F Mechinaud; J Bacher; J Lee; M Rubin; P A Pizzo
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

Review 5.  Treatment of systemic fungal infections: recent progress and current problems.

Authors:  T J Walsh; A Pizzo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

6.  In vitro and in vivo anti-Candida activity and toxicology of LY121019.

Authors:  R S Gordee; D J Zeckner; L F Ellis; A L Thakkar; L C Howard
Journal:  J Antibiot (Tokyo)       Date:  1984-09       Impact factor: 2.649

7.  Evaluation of cilofungin (LY121019) for treatment of experimental Candida albicans endocarditis in rabbits.

Authors:  A Padula; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

  7 in total
  11 in total

1.  Treatment of murine disseminated candidiasis with L-743,872.

Authors:  J R Graybill; L K Najvar; M F Luther; A W Fothergill
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Efficacy of cilofungin therapy administered by continuous intravenous infusion for experimental disseminated candidiasis in rabbits.

Authors:  M S Rouse; B M Tallan; J M Steckelberg; N K Henry; W R Wilson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

3.  Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits.

Authors:  A H Groll; B M Gullick; R Petraitiene; V Petraitis; M Candelario; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

4.  Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.

Authors:  V Petraitis; R Petraitiene; A H Groll; T Sein; R L Schaufele; C A Lyman; A Francesconi; J Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

5.  Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).

Authors:  R Hajdu; R Thompson; J G Sundelof; B A Pelak; F A Bouffard; J F Dropinski; H Kropp
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling.

Authors:  A H Groll; D Mickiene; R Petraitiene; V Petraitis; C A Lyman; J S Bacher; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 7.  Compounds active against cell walls of medically important fungi.

Authors:  R F Hector
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

8.  Comparative efficacies of cilofungin (Ly121019) and amphotericin B against disseminated Candida albicans infection in normal and granulocytopenic mice.

Authors:  N Khardori; H Nguyen; L C Stephens; L Kalvakuntla; B Rosenbaum; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

9.  Antifungal effects of the nonlinear pharmacokinetics of cilofungin, a 1,3-beta-glucan synthetase inhibitor, during continuous and intermittent intravenous infusions in treatment of experimental disseminated candidiasis.

Authors:  T J Walsh; J W Lee; P Kelly; J Bacher; J Lecciones; V Thomas; C Lyman; D Coleman; R Gordee; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

Review 10.  Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications.

Authors:  C A Lyman; T J Walsh
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.